December 5 - 8, 2009
New Orleans, Louisiana, USA
Findings from the Phase III EINSTEIN-Extension study have been presented in the Late Breaking Abstract Session on December 8, 2009 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.
On this occasion we held a conference call for investors and analysts.
with
Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
Background Information | |
|---|---|
About Xarelto® |
|
About EINSTEIN Studies |
|
Rivaroxaban Clinical Trial Program |
|
Rivaroxaban Bibliography |
|
About Venous Thromboembolism (VTE) |
|
Glossary |
|
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
collect